

Paweł, Buszman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3598158/publications.pdf>

Version: 2024-02-01

79
papers

9,078
citations

117453

34
h-index

71532

76
g-index

81
all docs

81
docs citations

81
times ranked

8379
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of long-term outcomes after directional versus rotational atherectomy in peripheral artery disease. <i>Postępy W Kardiologii Interwencyjnej</i> , 2020, 16, 76-81.	0.1	0
2	2-Year Clinical Outcomes of an Abluminal Groove-Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1679-1687.	1.1	14
3	New-Onset Atrial Fibrillation After PCI or CABG for Left Main Disease. <i>Journal of the American College of Cardiology</i> , 2018, 71, 739-748.	1.2	94
4	An optical coherence tomography study of neointimal morphology and strut coverage at different time intervals from implantation of biodegradable polymer-coated sirolimus-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 302-309.	0.7	5
5	Safety and feasibility of same-day early discharge after endovascular revascularization of lower extremities in elderly. <i>SENIOR registry</i> . <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 515-520.	0.7	2
6	Extracellular Matrix Proteomics Reveals Interplay of Aggrecan and Aggrecanases in Vascular Remodeling of Stented Coronary Arteries. <i>Circulation</i> , 2018, 137, 166-183.	1.6	77
7	A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial. <i>Lancet, The</i> , 2018, 391, 431-440.	6.3	70
8	Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial. <i>Lancet, The</i> , 2018, 392, 1117-1126.	6.3	46
9	Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. <i>Lancet, The</i> , 2018, 392, 940-949.	6.3	555
10	Selected adipokines and thickness of the intima-media complex in patients with systemic lupus erythematosus. <i>Kardiologia Polska</i> , 2018, 76, 917-919.	0.3	3
11	Rotational atherectomy in everyday clinical practice. Association of Cardiovascular Interventions of the Polish Society of Cardiology (Asocjacja Interwencji Sercowo-Naczyniowych Polskiego) <i>Tj ETQq1 1 0.784314 rgBTj Overlook 10 Tf 50</i>		
12	A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the DAPT-STEMI trial. <i>American Heart Journal</i> , 2017, 188, 11-17.	1.2	13
13	Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study. <i>European Heart Journal</i> , 2017, 38, 3124-3134.	1.0	244
14	State-of-the-art of transcatheter treatment of aortic valve stenosis and the overview of the InFlow project aiming at developing the first Polish TAVI system. <i>Cardiology Journal</i> , 2017, 24, 685-694.	0.5	1
15	New treatment possibilities for patients with advanced coronary artery disease and critical limb ischemia – a feasibility study. <i>Postępy W Kardiologii Interwencyjnej</i> , 2016, 4, 368-371.	0.1	0
16	First generation versus second generation drug-eluting stents for the treatment of bifurcations: 5-year follow-up of the LEADERS all-comers randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, E248-60.	0.7	44
17	Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2016, 375, 2223-2235.	13.9	843
18	Renal Artery Stenting Associated With Improvement in Renal Function and Blood Pressure Control in Long-Term Follow-Up. <i>Kidney and Blood Pressure Research</i> , 2016, 41, 278-287.	0.9	7

#	ARTICLE	IF	CITATIONS
19	Reduced risk of myocardial infarct and revascularization following coronary artery bypass grafting compared with percutaneous coronary intervention in patients with chronic kidney disease. <i>Kidney International</i> , 2016, 90, 411-421.	2.6	38
20	Treatment of Chronic Functional Mitral Valve Regurgitation With a Percutaneous Annuloplasty System. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2927-2936.	1.2	105
21	A Nuclear Magnetic Resonance Spectroscopy as a Method for Evaluation of In Vivo Poly-L-lactide Biodegradation Kinetics From Stent-Polymer Matrices. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2016, 21, 93-99.	1.0	7
22	Causes of hospitalisation and prognosis in patients with cardiovascular diseases – secular trends 2006-2014. Silesian Cardiovascular (SILCARD) database covering a population of 4.6 million subjects. <i>Polish Archives of Internal Medicine</i> , 2016, 126, 754-762.	0.3	12
23	Comparable vascular response of a new generation sirolimus eluting stents when compared to fluoropolymer everolimus eluting stents in the porcine coronary restenosis model. <i>Cardiology Journal</i> , 2016, 23, 657-666.	0.5	12
24	Five-year outcomes of chronic total occlusion treatment with a biolimus A9-eluting biodegradable polymer stent versus a sirolimus-eluting permanent polymer stent in the LEADERS all-comers trial. <i>Cardiology Journal</i> , 2016, 23, 626-636.	0.5	3
25	Effects of renal sympathetic denervation on blood pressure and glycaemic control in patients with true resistant hypertension: results of Polish Renal Denervation Registry (RDN-POL Registry). <i>Kardiologia Polska</i> , 2016, 74, 961-968.	0.3	7
26	Treatment of symptomatic coronary artery disease in patients with end-stage renal disease on hemodialysis with paclitaxel-eluting TAXUS stent. <i>Hemodialysis International</i> , 2015, 19, 402-411.	0.4	3
27	A Novel Peritoneum Derived Vascular Prosthesis Formed on a Latex Catheter in an SDF-1 Chemokine Enriched Environment: A Pilot Study. <i>International Journal of Artificial Organs</i> , 2015, 38, 89-95.	0.7	3
28	Comparison of Zotarolimus- and Everolimus-Eluting Coronary Stents. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002230.	1.4	122
29	Stenting and Adjunctive Delivery of Paclitaxel Via Balloon Coating Versus Durable Polymeric Matrix for De Novo Coronary Lesions: Clinical and Angiographic Results from the Prospective Randomized Trial. <i>Journal of Interventional Cardiology</i> , 2015, 28, 348-357.	0.5	12
30	Experimental evaluation of pharmacokinetic profile and biological effect of a novel paclitaxel microcrystalline balloon coating in the iliofemoral territory of swine. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, 325-333.	0.7	19
31	Long-Term Outcomes of Percutaneous Coronary Interventions or Coronary Artery Bypass Grafting for Left Main Coronary Artery Disease in Octogenarians (from a Drug-Eluting stent for Left main) <i>TJ EQq1 1 0.784617 rgBT 10</i>	0.7	16
32	Comparison of Stenting and Surgical Revascularization Strategy in Non-ST Elevation Acute Coronary Syndromes and Complex Coronary Artery Disease (from the Milestone Registry). <i>American Journal of Cardiology</i> , 2014, 114, 979-987.	0.7	16
33	4-Year Clinical Outcomes and Predictors of Repeat Revascularization in Patients Treated With New-Generation Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1617-1625.	1.2	152
34	Differences in vessel healing following delivery of everolimus or paclitaxel: a comparative experimental study using identical stent and biodegradable polymer platforms. <i>EuroIntervention</i> , 2014, 10, 724-731.	1.4	8
35	Long-term results of plaque excision combined with aggressive pharmacotherapy in high-risk patients with advanced peripheral artery disease (SAVE a LEG registry). <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, E244-50.	0.7	4
36	Improved Safety and Reduction in Stent Thrombosis Associated With Biodegradable Polymer-Based Biolimus-Eluting Stents Versus Durable Polymer-Based Sirolimus-Eluting Stents in Patients With Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 777-789.	1.1	296

#	ARTICLE	IF	CITATIONS
37	Comparable clinical safety and efficacy of biodegradable versus durable polymer paclitaxel eluting stents despite shorter dual antiplatelet therapy: Insights from a multicenter, propensity score-matched registry. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, E155-62.	0.7	6
38	Controlled Reperfusion with Intravenous Bivalirudin and Intracoronary Abciximab Combination Therapy in the Porcine Myocardial Infarction Model. <i>Thrombosis Research</i> , 2012, 130, 265-272.	0.8	15
39	Drug-Eluting Stent for Left Main Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 718-727.	1.1	121
40	Effects of intracoronary delivery of allogenic bone marrow-derived stem cells expressing heme oxygenase-1 on myocardial reperfusion injury. <i>Thrombosis and Haemostasis</i> , 2012, 108, 464-475.	1.8	21
41	Long-term results of cephalad arteries percutaneous transluminal angioplasty with stent implantation (The CAPTAS registry). <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 532-540.	0.7	4
42	The Impact of Patient and Lesion Complexity on Clinical and Angiographic Outcomes After Revascularization With Zotarolimus- and Everolimus-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2221-2232.	1.2	101
43	2-Year Clinical Follow-Up From the Randomized Comparison of Biolimus-Eluting Stents With Biodegradable Polymer and Sirolimus-Eluting Stents With Durable Polymer in Routine Clinical Practice. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 887-895.	1.1	32
44	Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. <i>Lancet, The</i> , 2011, 378, 1940-1948.	6.3	321
45	Taxcor for the prevention of restenosis. Polish multicentre observational study to assess the efficacy and safety of the Genius TAXCOR I stent. <i>Postępy W Kardiologii Interwencyjnej</i> , 2011, 4, 285-291.	0.1	0
46	Giant aneurysm in medial anterior descending artery: treatment with two endovascular stent grafts on bare metal stent scaffold. <i>Postępy W Kardiologii Interwencyjnej</i> , 2011, 2, 173-177.	0.1	0
47	Intracoronary adiponectin at reperfusion reduces infarct size in a porcine myocardial infarction model. <i>International Journal of Molecular Medicine</i> , 2011, 27, 775-81.	1.8	14
48	Effects of local intracoronary paclitaxel delivery using the Remedy transport catheter on neointimal hyperplasia after stent implantation in a porcine model. <i>Cardiovascular Revascularization Medicine</i> , 2011, 12, 82-89.	0.3	2
49	The Prognostic Utility of the SYNTAX Score on 1-Year Outcomes After Revascularization With Zotarolimus- and Everolimus-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 432-441.	1.1	98
50	Value of Age, Creatinine, and Ejection Fraction (ACEF Score) in Assessing Risk in Patients Undergoing Percutaneous Coronary Interventions in the "All-Comers" LEADERS Trial. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 47-56.	1.4	109
51	The outcome of bifurcation lesion stenting using a biolimus-eluting stent with a bio-degradable polymer compared to a sirolimus-eluting stent with a durable polymer. <i>EuroIntervention</i> , 2011, 6, 928-935.	1.4	19
52	Implantation of the biodegradable polymer biolimus-eluting stent in patients with high SYNTAX score is associated with decreased cardiac mortality compared to a permanent polymer sirolimus-eluting stent: two year follow-up results from the "Call-comers" LEADERS trial. <i>EuroIntervention</i> , 2011, 7, 605-613.	1.4	21
53	The three year follow-up of the randomised "all-comers" trial of a biodegradable polymer biolimus-eluting stent versus permanent polymer sirolimus-eluting stent (LEADERS). <i>EuroIntervention</i> , 2011, 7, 789-795.	1.4	36
54	The Impact of Body Mass Index on the One Year Outcomes of Patients Treated by Percutaneous Coronary Intervention With Biolimus- and Sirolimus-Eluting Stents (from the LEADERS Trial). <i>American Journal of Cardiology</i> , 2010, 105, 475-479.	0.7	49

#	ARTICLE	IF	CITATIONS
55	Value of the SYNTAX Score for Risk Assessment in the All-Comers Population of the Randomized Multicenter LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) Trial. <i>Journal of the American College of Cardiology</i> , 2010, 56, 272-277.	1.2	198
56	Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents. <i>New England Journal of Medicine</i> , 2010, 363, 136-146.	13.9	608
57	The twelve-month outcomes of a biolimus eluting stent with a biodegradable polymer compared with a sirolimus eluting stent with a durable polymer. <i>EuroIntervention</i> , 2010, 6, 233-239.	1.4	49
58	Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. <i>European Heart Journal</i> , 2009, 30, 1313-1321.	1.0	427
59	Angiographic and clinical outcomes of drug-eluting versus bare metal stent deployment in the Occluded Artery Trial. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 73, 771-779.	0.7	8
60	Percutaneous versus surgical revascularization for multivessel coronary artery disease: A single center 10 year follow-up of SOS trial patients. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 74, 420-426.	0.7	7
61	Drug Delivery at the Aortic Valve Tissues of Healthy Domestic Pigs with a Paclitaxel-Eluting Valvuloplasty Balloon. <i>Journal of Interventional Cardiology</i> , 2009, 22, 291-298.	0.5	9
62	Impact of Vessel Size on Angiographic and Clinical Outcomes of Revascularization With Biolimus-Eluting Stent With Biodegradable Polymer and Sirolimus-Eluting Stent With Durable Polymer. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 861-870.	1.1	48
63	Percutaneous coronary intervention in the Occluded Artery Trial: Procedural success, hazard, and outcomes over 5 years. <i>American Heart Journal</i> , 2009, 158, 408-415.	1.2	12
64	Mobilization of Bone Marrow-Derived Oct-4+ SSEA-4+ Very Small Embryonic-Like Stem Cells in Patients With Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1-9.	1.2	835
65	Biolimus-eluting biodegradable polymer versus sirolimus-eluting permanent polymer stent performance in long lesions: results from the LEADERS multicentre trial substudy. <i>EuroIntervention</i> , 2009, 5, 310-317.	1.4	14
66	Novel paclitaxel-eluting, biodegradable polymer coated stent in the treatment of de novo coronary lesions: A prospective multicenter registry. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 71, 51-57.	0.7	30
67	Acute and Late Outcomes of Unprotected Left Main Stenting in Comparison With Surgical Revascularization. <i>Journal of the American College of Cardiology</i> , 2008, 51, 538-545.	1.2	352
68	Percutaneous Coronary Intervention or Coronary Artery Bypass Graft for Unprotected Left Main Coronary Artery Disease: The Endless Debate. <i>Journal of the American College of Cardiology</i> , 2008, 52, 582-584.	1.2	6
69	Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. <i>Lancet</i> , The, 2008, 372, 1163-1173.	6.3	607
70	Effects of the Direct Lipoprotein-Associated Phospholipase A ₂ Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque. <i>Circulation</i> , 2008, 118, 1172-1182.	1.6	492
71	Comparison of Effectiveness of Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention in Patients With Ischemic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2007, 99, 36-41.	0.7	39
72	Use of multidetector computed tomography for the assessment of acute chest pain: a consensus statement of the North American Society of Cardiac Imaging and the European Society of Cardiac Radiology. <i>European Radiology</i> , 2007, 17, 2196-2207.	2.3	63

#	ARTICLE	IF	CITATIONS
73	Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. <i>European Heart Journal</i> , 2006, 27, 1341-1381.	1.0	1,192
74	Randomized Trial of Percutaneous Coronary Intervention for Subacute Infarct-Related Coronary Artery Occlusion to Achieve Long-Term Patency and Improve Ventricular Function. <i>Circulation</i> , 2006, 114, 2449-2457.	1.6	139
75	Usefulness of Stanford Scale of Intimal Hyperplasia Assessed by Intravascular Ultrasound to Predict Time of Onset and Severity of Cardiac Allograft Vasculopathy. <i>Transplantation Proceedings</i> , 2005, 37, 1343-1345.	0.3	8
76	The new Polish stent Chopin. Assessment of safety and efficacy in the treatment of de-novo coronary lesions using percutaneous angioplasty. <i>Kardiologia Polska</i> , 2005, 62, 451-9; discussion 460-1.	0.3	1
77	Local Delivery of Enoxaparin to Decrease Restenosis After Stenting: Results of Initial Multicenter Trial. <i>Circulation</i> , 2001, 103, 26-31.	1.6	53
78	A randomized comparison of elective high-pressure stenting with balloon angioplasty: Six-month angiographic and two-year clinical follow-up. <i>American Heart Journal</i> , 2000, 140, 264-271.	1.2	15
79	Use of changes in ST segment elevation for prediction of infarct artery recanalization in acute myocardial infarction. <i>European Heart Journal</i> , 1995, 16, 1207-1214.	1.0	21